How to buy Clinuvel Pharmaceuticals (CUV) shares

Learn how to easily invest in Clinuvel Pharmaceuticals shares.

Clinuvel Pharmaceuticals Limited
AU: CUV - AUD
BIOTECHNOLOGY
A$43.26
- A$0.32 ( - 0.73%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Clinuvel Pharmaceuticals Limited is a biotechnology business based in Australia. Clinuvel Pharmaceuticals shares (CUV) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Clinuvel Pharmaceuticals has a trailing 12-month revenue of around $48 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Clinuvel Pharmaceuticals

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Clinuvel Pharmaceuticals. Find the share by name or ticker symbol: CUV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Clinuvel Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Clinuvel Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Clinuvel Pharmaceuticals stock price (ASX:CUV)

Use our graph to track the performance of CUV stocks over time.

Clinuvel Pharmaceuticals shares at a glance

Information last updated 2021-09-24.
52-week range$19.6165 - $44.67
50-day moving average $34.5168
200-day moving average $30.0641
Target price$33.92
PE ratio 89.3802
Dividend yield $0.025 (0.06%)
Earnings per share (TTM) $0.484

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
AUD $5
No
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
ThinkMarkets Share Trading
AUD $8
No
ASX shares
Limited-time offer: Get 10 free ASX trades ($0 brokerage) when you open a share trading account with ThinkMarkets(T&Cs apply).$8 flat fee brokerage for CHESS Sponsored ASX stocks (HIN ownership), plus free live stock price data on an easy to use mobile app.
Saxo Capital Markets (Classic account)
AUD $5
No
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
AUD $11 or 0.1%
No
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
HSBC Online Share Trading
AUD $19.95
No
ASX shares, mFunds, ETFs, Bonds
Limited time offer: Get up to $100 in brokerage rebates on your first 5 trades when you sign up to a HSBC Online Share Trading account (T&Cs apply). Make trades online with brokerage fees starting from just $19.95 with an HSBC Online Share Trading account. Plus gain access to complimentary expert research, trading ideas and tools.
Bell Direct Share Trading
AUD $15
No
ASX shares, mFunds, ETFs
Invest in Australian shares, options and managed funds from the one account with no inactivity fee.
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
loading

Compare up to 4 providers

Is it a good time to buy Clinuvel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Clinuvel Pharmaceuticals price performance over time

Historical closes compared with the last close of A$43.26

1 week (2021-09-17) 3.72%
1 month (2021-08-25) 52.59%
3 months (2021-06-25) 51.95%
6 months (2021-03-25) 51.90%
1 year (2020-09-25) 84.32%
2 years (2019-09-25) 74.01%
3 years (2018-09-25) 104.06%
5 years (2016-09-23) 609.18%

Is Clinuvel Pharmaceuticals under- or over-valued?

Valuing Clinuvel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinuvel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clinuvel Pharmaceuticals's P/E ratio

Clinuvel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 89x. In other words, Clinuvel Pharmaceuticals shares trade at around 89x recent earnings.

That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Clinuvel Pharmaceuticals's EBITDA

Clinuvel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $28.7 million (£0.0 million).

The EBITDA is a measure of a Clinuvel Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Clinuvel Pharmaceuticals financials

Revenue TTM $48 million
Operating margin TTM 58.83%
Gross profit TTM $41.2 million
Return on assets TTM 18.56%
Return on equity TTM 28.96%
Profit margin 51.54%
Book value 1.998
Market capitalisation $2.1 billion

TTM: trailing 12 months

Clinuvel Pharmaceuticals share dividends

5%

Dividend payout ratio: 5.32% of net profits

Recently Clinuvel Pharmaceuticals has paid out, on average, around 5.32% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.06% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinuvel Pharmaceuticals shareholders could enjoy a 0.06% return on their shares, in the form of dividend payments. In Clinuvel Pharmaceuticals's case, that would currently equate to about A$0.025 per share.

While Clinuvel Pharmaceuticals's payout ratio might seem low, this can signify that Clinuvel Pharmaceuticals is investing more in its future growth.

The latest dividend was paid out to all shareholders who bought their shares by 1 September 2021 (the "ex-dividend date").

Have Clinuvel Pharmaceuticals's shares ever split?

Clinuvel Pharmaceuticals's shares were split on a 1:10 basis on 11 November 2010. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Clinuvel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Clinuvel Pharmaceuticals shares which in turn could have impacted Clinuvel Pharmaceuticals's share price.

Clinuvel Pharmaceuticals share price volatility

Over the last 12 months, Clinuvel Pharmaceuticals's shares have ranged in value from as little as $19.6165 up to $44.67. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Clinuvel Pharmaceuticals's is 0.4555. This would suggest that Clinuvel Pharmaceuticals's shares are less volatile than average (for this exchange).

Clinuvel Pharmaceuticals overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site